Good post slcimmuno... Fully agree, but, I'll add that any large pharma looking to partner/license will also understand this even if most investors don't.
In Reply to 'slcimmuno'
for reals now - i simply linked to / cut-paste my response to a post of yours ---- primary imo will be met and moreover, shored up with secondary/exploratory endpoints
what you fail to understand is that most other OM drugs in trial are going after Duration / Onset not Incident as primary
so by def IPIX could fail its primary (Incidence) but still perform well as others in the secondary (Onset, Duration)
market might care (prob though because it might not understand as well as some of us IPIX trial design), but FDA sure wouldn't care which is Primary, which is Secondary --
it'll all come down the FULL dataset ... Incidence, Onset, Duration... plus all the other measures
case closed
News 
Market Data 
Discover 
AI
